Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130312 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12231487 | 0.95 | TAS1R3 (0.40) | TAS1R3TAS1R1EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18412740 | 0.95 | TAS1R3 (0.40) | TAS1R3TAS1R1EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14268028 | 0.95 | TAS1R3 (0.40) | TAS1R3TAS1R1EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23722403 | 0.83 | TAS1R3 (0.41) | TAS1R3TAS1R1EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13303583 | 0.83 | PIM1 (0.42) | TAS1R3TAS1R1PIM1KDM4E | |
| SCHEMBL20061124 | 0.83 | PIM1 (0.42) | TAS1R3TAS1R1PIM1KDM4E | |
| SCHEMBL4417021 | 0.83 | PIM1 (0.42) | TAS1R3TAS1R1PIM1KDM4E | |
| SCHEMBL22647693 | 0.80 | PIM1 (0.41) | TAS1R3TAS1R1EPHX1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL6656735 | 0.78 | PIM1 (0.40) | TAS1R3TAS1R1PIM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | UNIV JOHNS HOPKINS (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2012151567-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TAS1R3 1218/4885TAS1R1 1469/4885EPHX1 4407/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | TAS1R3 4475/4885TAS1R1 3974/4885EPHX1 942/4885 |
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | IDO2, IDO1, INMT | TAS1R3 4529/4885TAS1R1 4601/4885EPHX1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.